| Literature DB >> 21407822 |
Masaya Takemura1, Katsumi Mitsui, Ryo Itotani, Manabu Ishitoko, Shinko Suzuki, Masataka Matsumoto, Kensaku Aihara, Tsuyoshi Oguma, Tetsuya Ueda, Hitoshi Kagioka, Motonari Fukui.
Abstract
PURPOSE: Adherence to inhalation therapy is a critical determinant of the success of chronic obstructive pulmonary disease (COPD) management. However, in practice, nonadherence to inhalation therapy is very common in COPD patients. The effects of adherence to inhalation therapy in COPD have not been fully studied, and less is known about the relationship between medication adherence and quality of life in COPD. Our aim is to assess the factors that contribute to adherence to inhalation therapy and examine their correlation with quality of life. PATIENTS AND METHODS: A cross-sectional analysis of 88 COPD patients was performed using a self-reported adherence questionnaire with responses on a 5-point Likert scale.Entities:
Keywords: COPD; adherence; quality of life; repeated instruction
Mesh:
Substances:
Year: 2011 PMID: 21407822 PMCID: PMC3048085 DOI: 10.2147/COPD.S16173
Source DB: PubMed Journal: Int J Chron Obstruct Pulmon Dis ISSN: 1176-9106
Adherence questionnaire
| During the last 3 months have you:
Been careless about using your inhaler? Ever forgotten to use your inhaler? Ever stopped using your inhaler because you felt better? Used your inhaler less than your doctor prescribed because you felt better? | ||||
| Responses were as follows: | ||||
| Most of the time | Some of the time | None of the time | ||
| 1 | 2 | 3 | 4 | 5 |
Survey respondents’ background and characteristics of patients with and without adherence to inhalation therapy
| Total | Adherence | |||
|---|---|---|---|---|
| Good | Poor | |||
| Patients (number) | 55 | 30 | 25 | |
| Age (years) | 69 ± 8 | 70 ± 8 | 67 ± 7 | 0.11 |
| Gender (female) | 15 | 8 | 7 | >0.99 |
| Current smoking (yes) | 8 | 6 | 2 | >0.99 |
| Frequency of clinic visits | 8 (4–18) | 7.5 (4–16) | 8 (4–18) | 0.80 |
| Duration of disease (years) | 9 ± 9 | 8 ± 9 | 9 ± 17 | 0.09 |
| Period of inhaler use (years) | 6 ± 6 | 6 ± 6 | 5 ± 8 | 0.10 |
| Frequency of inhaler use (per day) | 2.4 ± 1.0 | 2.3 ± 0.7 | 2.0 ± 0.6 | 0.11 |
| Type of inhaler device (DPI, MDI, and DPI + MDI) | 18, 18, 19 | 10, 10, 10 | 8, 9, 8 | 0.98 |
| Presence of comorbidities | 37 | 20 | 17 | >0.99 |
| Taking of antipsychotic drugs | 13 | 8 | 5 | 0.75 |
| Stage of COPD (I, II, III, IV) | 13, 30, 9, 3 | 6, 17, 5, 2 | 7, 13, 4, 1 | 0.89 |
| FEV1% predicted value (%) | 68.1 ± 16.0 | 68.4 ± 16.2 | 67.6 ± 16.2 | 0.91 |
| FEV1/FVC (%) | 56.3 ± 13.1 | 57.2 ± 13.3 | 54.0 ± 13.3 | 0.37 |
| Presence of repeated instruction | 22 | 16 | 6 | 0.033 |
| Overall mean adherence score | 4.1 ± 0.7 | 4.6 ± 0.4 | 3.3 ± 0.3 | <0.001 |
Notes: Median value. Good adherence was defined by an overall mean adherence score ≥4.0, and poor adherence means score <4.0.
Abbreviations: DPI, dry powder inhaler; MDI, metered-dose inhaler.
Multiple stepwise regression of the variables related to the good adherence to inhalation therapy
| Standardized coefficients beta | |||
|---|---|---|---|
| Age | 0.22 | 1.56 | 0.13 |
| Gender | −0.06 | −0.42 | 0.68 |
| Frequency of clinic visits | −0.01 | −0.05 | 0.96 |
| Frequency of inhaler use | 0.19 | 1.39 | 0.17 |
| Type of inhaler device | −0.02 | −0.14 | 0.89 |
| Comorbidities | −0.11 | 0.71 | 0.48 |
| Antipsychotic drugs | 0.06 | 0.42 | 0.68 |
| Stage of COPD | 0.12 | 0.86 | 0.39 |
| Repeated instruction | 0.28 | 2.13 | 0.040 |
Notes: Adjusted for female sex (yes = 1, no = 0), use of DPI + MDI-type inhaler (yes = 1, no = 0), presence of comorbidities (yes = 1, no = 0), taking of antipsychotic drugs (yes = 1, no = 0), and presence of repeated instruction (yes = 1, no = 0).
Abbreviations: DPI, dry powder inhaler; MDI, metered-dose inhaler.
Figure 1Comparison of overall mean adherence scores between COPD patients with and without repeated instruction for inhalation technique.
Comparisons of mean adherence scores for individual items between patients with and without repeated instruction
| Repeated instruction | |||
|---|---|---|---|
| Yes | No | ||
| Patients, no. | 22 | 33 | |
| Overall mean adherence score | 4.4 ± 0.5 | 3.9 ± 0.8 | 0.032 |
| Questionnaire item | |||
| Careless about inhaler | 4.3 ± 1.1 | 4.0 ± 1.1 | 0.16 |
| Forgot to use inhaler | 4.3 ± 1.0 | 4.0 ± 1.0 | 0.40 |
| Stopped using inhaler because felt better | 4.6 ± 0.7 | 4.0 ± 1.1 | 0.049 |
| Used inhaler less because felt better | 4.5 ± 0.7 | 3.9 ± 1.2 | 0.062 |
Correlation between overall mean adherence score and SGRQ scores
| Total | −0.35 | 0.023 |
| Symptoms | −0.43 | 0.002 |
| Activities | −0.17 | 0.21 |
| Impacts | −0.35 | 0.011 |
Abbreviation: SGRQ, St George’s Respiratory Questionnaire.
Multiple stepwise regression of the variables related to the total SGRQ score
| Standardized coefficients beta | |||
|---|---|---|---|
| Age | 0.07 | 0.55 | 0.59 |
| Gender | 0.30 | 2.35 | 0.023 |
| Frequency of clinic visits | 0.02 | 0.12 | 0.90 |
| Frequency of inhaler use | 0.14 | 1.03 | 0.31 |
| Type of inhaler device | 0.13 | 1.03 | 0.31 |
| Comorbidities | 0.19 | 1.35 | 0.18 |
| Antipsychotic drugs | 0.06 | 0.42 | 0.68 |
| Stage of COPD | 0.01 | 0.10 | 0.93 |
| Repeated instruction | −0.32 | −2.48 | 0.017 |
Notes: Adjusted for female sex (yes = 1, no = 0), use of DPI + MDI-type inhaler (yes = 1, no = 0), presence of comorbidities (yes = 1, no = 0), taking of antipsychotic drugs (yes = 1, no = 0), and presence of repeated instruction (yes = 1, no = 0).
Abbreviations: DPI, dry powder inhaler; MDI, metered-dose inhaler.